Achieve Life Sciences (ACHV) Assets Average (2011 - 2026)
Achieve Life Sciences' (ACHV) quarterly Assets Average came in at $37.4 million in Q1 2026, up 13.49% YoY from $33.0 million in Q1 2025, and down 20.18% on a QoQ basis from $46.9 million in Q4 2025.
Achieve Life Sciences (ACHV) Assets Average (2011 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 16 years of Assets Average data on file, last reported at $37.4 million in Q1 2026.
- Quarterly Assets Average rose 13.49% year-over-year to $37.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.4 million (up 13.49% YoY) and the FY2025 annual result came in at $40.2 million, up 38.65% from the prior year.
- Assets Average declined to $37.4 million in Q1 2026, from $46.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $67.4 million in Q2 2024 to a low of $21.9 million in Q4 2023.
- A 5-year average of $39.0 million and a median of $37.4 million in 2026 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average sank 42.39% — and 2024, when it soared 171.2%.
- Tracing ACHV's Assets Average over 5 years: stood at $26.8 million in 2022, then dropped by 18.6% to $21.9 million in 2023, then soared by 98.02% to $43.3 million in 2024, then grew by 8.41% to $46.9 million in 2025, then slipped by 20.18% to $37.4 million in 2026.
- The last three Assets Average figures came in at $37.4 million (Q1 2026), $46.9 million (Q4 2025), and $55.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 111.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.77 Mn |
| Mar 31, 2026 | 37.45 Mn |
| Dec 31, 2025 | 46.92 Mn |
| Sep 30, 2025 | 55.49 Mn |
| Jun 30, 2025 | 43.15 Mn |
| Mar 31, 2025 | 33.00 Mn |
| Dec 31, 2024 | 43.28 Mn |
| Sep 30, 2024 | 56.35 Mn |
| Jun 30, 2024 | 67.41 Mn |
| Mar 31, 2024 | 44.70 Mn |
| Dec 31, 2023 | 21.85 Mn |
| Sep 30, 2023 | 26.63 Mn |
| Jun 30, 2023 | 24.86 Mn |
| Mar 31, 2023 | 25.38 Mn |
| Dec 31, 2022 | 26.85 Mn |
| Sep 30, 2022 | 28.85 Mn |
| Jun 30, 2022 | 37.30 Mn |
| Mar 31, 2022 | 44.07 Mn |
| Dec 31, 2021 | 42.66 Mn |
| Sep 30, 2021 | 41.68 Mn |